Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
Summary
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.
Outcome measures
Primary
Overall survival (OS)
Time from radiotherapy start until death from any cause
Time frame: Up to 5 years
Secondary
Progression-free survival (PFS)
Time frame: Up to 5 years
Eligibility criteria
Study locations (4)
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai
New York, New York, 10017
Department of Radiation Oncology, Case Western Reserve University
Cleveland, Ohio, 10900
Division of Radiation Oncology, The Ohio State University Wexner
Columbus, Ohio, 43201